» Articles » PMID: 30188694

MRNA Polyplexes with Post-Conjugated GALA Peptides Efficiently Target, Transfect, and Activate Antigen Presenting Cells

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2018 Sep 7
PMID 30188694
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines based on mRNA have emerged as potent systems to elicit CD8 T cell responses against various cancers and viral infectious diseases. The efficient intracellular delivery of mRNA molecules encoding antigens into the cytosol of antigen-presenting cells (APCs) is still challenging, requiring cell attachment, active uptake, and subsequent endosomal escape. Here, we report a facile approach for the formulation of peptide-functionalized mRNA polyplexes using copper-free click chemistry to promote presentation of mRNA antigen by dendritic cells (DCs). After screening different membrane active peptides, GALA modified mRNA polyplexes (PPx-GALA) with a size around 350 nm and with a slightly negative surface charge (-7 mV), exhibited the highest EGFP-mRNA transfection in RAW 246.7 macrophages (∼36%) and D1 dendritic cells (∼50%) as compared to polyplexes decorated with melittin or LEDE peptides. Interestingly, we found that PPx-GALA enters DCs through sialic acid mediated endo/phagocytosis, which was not influenced by DC maturation. The PPx-GALA formulation exhibited 18-fold higher cellular uptake compared to a lipofectamine mRNA formulation without inducing cytotoxicity. Live cell imaging showed that PPx-GALA that were taken up by endocytosis induced calcein release from endosomes into the cytosol. DCs treated with PPx-GALA containing mRNA encoding for OVA displayed enhanced T cell responses and DC maturation. Collectively, these data provide a strong rationale for further study of this PPx-GALA formulation in vivo as a promising mRNA vaccine platform.

Citing Articles

Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.


Tuning the tropism and infectivity of SARS-CoV-2 virus-like particles for mRNA delivery.

Yang Q, Davidson B, Pajic P, Chen X, Gokcumen O, Gao M Nucleic Acids Res. 2025; 53(5).

PMID: 40037714 PMC: 11879429. DOI: 10.1093/nar/gkaf133.


Respiratory delivered vaccines: Current status and perspectives in rational formulation design.

Wu L, Xu W, Jiang H, Yang M, Cun D Acta Pharm Sin B. 2025; 14(12):5132-5160.

PMID: 39807330 PMC: 11725141. DOI: 10.1016/j.apsb.2024.08.026.


Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.

Haghighi E, Abolmaali S, Dehshahri A, Mousavi Shaegh S, Azarpira N, Tamaddon A J Nanobiotechnology. 2024; 22(1):710.

PMID: 39543630 PMC: 11566655. DOI: 10.1186/s12951-024-02972-w.


Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines.

Zhang X, Li Y, Zhou Z ACS Omega. 2024; 9(6):6219-6234.

PMID: 38371811 PMC: 10870384. DOI: 10.1021/acsomega.3c08353.


References
1.
Lou B, De Beuckelaer A, Dakwar G, Remaut K, Grooten J, Braeckmans K . Post-PEGylated and crosslinked polymeric ssRNA nanocomplexes as adjuvants targeting lymph nodes with increased cytolytic T cell inducing properties. J Control Release. 2018; 284:73-83. DOI: 10.1016/j.jconrel.2018.06.010. View

2.
Kranz L, Diken M, Haas H, Kreiter S, Loquai C, Reuter K . Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016; 534(7607):396-401. DOI: 10.1038/nature18300. View

3.
McKinlay C, Vargas J, Blake T, Hardy J, Kanada M, Contag C . Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A. 2017; 114(4):E448-E456. PMC: 5278438. DOI: 10.1073/pnas.1614193114. View

4.
Phua K, Leong K, Nair S . Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release. 2013; 166(3):227-33. PMC: 3594075. DOI: 10.1016/j.jconrel.2012.12.029. View

5.
Santiwarangkool S, Akita H, Nakatani T, Kusumoto K, Kimura H, Suzuki M . PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA. J Pharm Sci. 2017; 106(9):2420-2427. DOI: 10.1016/j.xphs.2017.04.075. View